Fuyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for bryprazole oral tablets issued by the State Drug Administration and approved the production of the drug. This drug is used to treat schizophrenia in adults, and the original research has not yet been marketed in China. The company obtained a notice of acceptance of the application on January 7, 2025, and was recently approved. Obtaining the “Drug Registration Certificate” this time is considered to have passed the consistency evaluation. As of the date of this announcement, the company's total R&D investment for this drug was RMB 5.7341 million.

Fuyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for bryprazole oral tablets issued by the State Drug Administration and approved the production of the drug. This drug is used to treat schizophrenia in adults, and the original research has not yet been marketed in China. The company obtained a notice of acceptance of the application on January 7, 2025, and was recently approved. Obtaining the “Drug Registration Certificate” this time is considered to have passed the consistency evaluation. As of the date of this announcement, the company's total R&D investment for this drug was RMB 5.7341 million.